TY - JOUR
KW - DPP4 inhibitor
KW - SGLT2 inhibitor
KW - diabetes complications
KW - Observational study
KW - population study
KW - Type 2 diabetes
AU - I. Idris
AU - R. Zhang
AU - J. Mamza
AU - M. Ford
AU - T. Morris
AU - A. Banerjee
AU - K. Khunti
AD - Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK.
Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Medical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca, London, UK.
Institute of Health Informatics, University College London, London, UK.
Department of Cardiology, University College London Hospitals, London, UK.
Diabetes Research Centre, University of Leicester, Leicester, UK.
AN - 35676798
BT - Diabetes Obes Metab
DO - 10.1111/dom.14799
DP - NLM
ET - 2022/06/10
LA - eng
N1 - 1463-1326
Idris, Iskandar
Zhang, Ruiqi
Mamza, Jil B
Ford, Mike
Morris, Tamsin
Banerjee, Amitava
Khunti, Kamlesh
Orcid: 0000-0003-2343-7099
AstraZeneca/
Horizon 2020/
European Union/
Innovative Medicines Initiative/
UK Research and Innovation/
the British Medical Association/
National Institute for Health and Care Research/
Biomedical Research Centre/
National Institute for Health Research/
Merck Sharp & Dohme/
Novo Nordisk/
Boehringer Ingelheim/
DH_/Department of Health/United Kingdom
Journal Article
England
Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14799.
PY - 2022
SN - 1462-8902
T2 - Diabetes Obes Metab
TI - Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting
ER -